Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Cassava Sciences Inc.

Wolf Haldenstein Adler Freeman & Herz LLP is LLC is investigating Cassava Sciences Inc. (NASDAQ: SAVA) (“Cassava” or the “Company”) for potential violations of federal securities laws.

If   you   purchased shares of  Cassava Sciences Inc. and suffered losses,  please call Gregory Stone at (800) 575-0735 or (212) 545-4774, email gstone@whafh.com or submit this form:

Cassava Sciences Inc. shares dropped precipitously today following a report that the Securities and Exchange Commission (“SEC”) has begun an investigation of the pharmaceutical company.
Securities regulators are examining claims that the company manipulated research results of its experimental Alzheimer’s disease treatment, the Wall Street Journal reported The National Institutes of Health, which provided grants to the company and its academic collaborators, is also looking into the claims, according to the report.

Shares of Cassava, fell to as low as $45.51 per share intraday, a decline of 27% from the prior day’s close.

In August, a former SEC enforcement lawyer filed a petition with the Food and Drug Administration (“FDA”) to halt studies of the company’s therapy, questioning the quality and integrity of its trial results. The company issued a statement at the time rejecting the claims.

Wolf Haldenstein Adler Freeman & Herz LLP  has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.